Slide 1: Q3 2025 Financial Results
NASDAQ: JYNT | © 2025 The Joint Corp. All Rights Reserved. Q3 2025 Financial Results As of September 30, 2025, reported on November 6, 2025 1
Slide 2: Safe Harbor Statements
NASDAQ: JYNT | © 2025 The Joint Corp. All Rights Reserved. Safe Harbor Statements Certain statements contained in this presentation are "forward-looking statements.“ Forward-looking statements are based on our beliefs, assumptions and expectations of industry trends, our future financial and operati
Slide 3: Sanjiv Razdan, CEO, President and Director
NASDAQ: JYNT | © 2025 The Joint Corp. All Rights Reserved. Sanjiv Razdan CEO, President and Director 3
Slide 4: Our Mission and Vision
NASDAQ: JYNT | © 2025 The Joint Corp. All Rights Reserved. OUR MISSION 4 is to improve quality of life through routine and affordable chiropractic care. OUR VISION is to build America’s most accessible health and wellness company.
Slide 5: Focused on Becoming a Pure Play Franchisor
NASDAQ: JYNT | © 2025 The Joint Corp. All Rights Reserved. Focused on Becoming a Pure Play Franchisor • Potential buyers identified for remaining corporate clinics • Actively engaged in negotiations for the balance of the corporate portfolio 5
Slide 6: Drive New Patient Acquisition
NASDAQ: JYNT | © 2025 The Joint Corp. All Rights Reserved. Drive New Patient Acquisition 6 • Shift to Pain: Focusing the top of the funnel messaging on pain relief, while continuing to support patients’ wellness journey • Increase National Marketing: Reallocating portion of local spend to national m
Slide 7: Debbie Gonzalez, Chief Marketing Officer
NASDAQ: JYNT | © 2025 The Joint Corp. All Rights Reserved. Debbie Gonzalez Chief Marketing Officer 7
Slide 8: Growing System-wide Sales
NASDAQ: JYNT | © 2025 The Joint Corp. All Rights Reserved. Growing System-wide Sales 8 • Launched 3 pricing pilots to inform enterprise-wide price increase in Q1 2026 • Kickstart plans started in July 2025 • ~25% of new patients buying packages
Slide 9: Elevating the Patient Experience
NASDAQ: JYNT | © 2025 The Joint Corp. All Rights Reserved. Elevating the Patient Experience 9 • Launched mobile app in July • Adoption by 18% of new patients • ~178k downloads • New release in August • Visit balance, plan type, cycle date, at-a-glance history, treatment plan and progress report look
Slide 10: Scott Bowman, Chief Financial Officer
NASDAQ: JYNT | © 2025 The Joint Corp. All Rights Reserved. Scott Bowman Chief Financial Officer 10
Slide 11: Operating Metrics
NASDAQ: JYNT | © 2025 The Joint Corp. All Rights Reserved. 11 36% Q3 2025 consolidated Adj. EBITDA increase over Q3 2024 (1.5)% Q3 2025 system-wide sales1 (2.0)% Q3 2025 comp sales2 1 System-wide sales include revenues at all clinics, whether operated or managed by the company or by franchisees. Whi
Slide 12: Total Clinics Open
NASDAQ: JYNT | © 2025 The Joint Corp. All Rights Reserved. 12 26 82 175 242 265 309 352 394 453 515 610 712 800 842 884 4 47 61 47 48 60 64 96 126 135 125 78 2010 2011 2012 2013 2014 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 Q3 2025 TOTAL CLINICS OPEN Franchised Company-owned or managed 52%
Slide 13: Q3 2025 Financial Results
NASDAQ: JYNT | © 2025 The Joint Corp. All Rights Reserved. 1 Due to rounding, numbers may not add up precisely to the totals. | 2 The results of the corporate clinic segment are reported in from discontinued operations and the franchised clinics in continued operations | 3 Reconciliation of Adjusted
Slide 14: YTD as of September 30, 2025
NASDAQ: JYNT | © 2025 The Joint Corp. All Rights Reserved. 1 Due to rounding, numbers may not add up precisely to the totals. | 2 The results of the corporate clinic segment are reported in from discontinued operations and the franchised clinics in continued operations | 3 Reconciliation of Adjusted
Slide 15: Strengthening Balance Sheet
NASDAQ: JYNT | © 2025 The Joint Corp. All Rights Reserved. Stock repurchase plan: • Purchased 540k shares for $5M August through November • Authorized for up to another $12M of outstanding common stock 1 JPMorgan Chase LOC provides immediate access to $20M through August 2027. Strengthening Balance
Slide 16: Revising 2025 Sales Guidance
NASDAQ: JYNT | © 2025 The Joint Corp. All Rights Reserved. Revising 2025 Sales Guidance 16 2024 2025 Prior Guidance 2025 Current Guidance $ in M Actual Low High Low High System-wide sales 1 $530.3 $530 $550 $530 $534 Comp sales 2 4% Low-single digits (1)% 0% Consolidated Adjusted EBTIDA $11.4 $10.8
Slide 17: Sanjiv Razdan, CEO, President and Director
NASDAQ: JYNT | © 2025 The Joint Corp. All Rights Reserved. Sanjiv Razdan CEO, President and Director 17
Slide 18: Committed to Driving Success
NASDAQ: JYNT | © 2025 The Joint Corp. All Rights Reserved. Net New Clinic Openings Adjusted EBITDA 18 Committed to Driving Success Comp Sales System-wide Sales
Slide 19: Performance Metrics and Non-GAAP Measures
NASDAQ: JYNT | © 2025 The Joint Corp. All Rights Reserved. Performance Metrics and Non-GAAP Measures 19 This presentation includes commonly discussed performance metrics. System-wide sales include revenues at all clinics, whether operated by the company or by franchisees. While franchised sales are
Slide 20: GAAP – Non-GAAP Reconciliation Quarterly Continuing Operations
NASDAQ: JYNT | © 2025 The Joint Corp. All Rights Reserved. GAAP – Non-GAAP Reconciliation Quarterly Continuing Operations 20
Slide 21: GAAP – Non-GAAP Reconciliation Quarterly Discontinued Operations
NASDAQ: JYNT | © 2025 The Joint Corp. All Rights Reserved. GAAP – Non-GAAP Reconciliation Quarterly Discontinued Operations 21
Slide 22: GAAP – Non-GAAP Reconciliation Quarterly Consolidated Operations
NASDAQ: JYNT | © 2025 The Joint Corp. All Rights Reserved. GAAP – Non-GAAP Reconciliation Quarterly Consolidated Operations 22
Slide 23: Contact
scott.bowman@thejoint.com Scott Bowman, CFO scott.bowman@thejoint.com The Joint Corp. | 16767 N. Perimeter Dr., Suite 110, Scottsdale, AZ 85260 | (480) 245-5960 https://www.facebook.com/thejointchiro https://twitter.com/thejointchiro https://www.youtube.com/thejointcorp https://www.facebook.com/thej